Possibly Disappointing Results of Treatment with Gemfibrozil
- 14 January 1993
- journal article
- letter
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 328 (2) , 139-140
- https://doi.org/10.1056/nejm199301143280214
Abstract
Many readers may have missed one of the most interesting items in the September 3 issue of the Journal: the fine print on the back of an advertisement for the Lopid brand of gemfibrozil. Gemfibrozil reduced the incidence of coronary events in the landmark Helsinki Heart Study, reported in the Journal in 19871. However, additional information about gemfibrozil that has since become available has received much less attention.Keywords
This publication has 7 references indexed in Scilit:
- Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment.Circulation, 1992
- Cholesterol, Primary and Secondary Prevention, and All-Cause MortalityAnnals of Internal Medicine, 1991
- The Value of Lowering Cholesterol after Myocardial InfarctionNew England Journal of Medicine, 1990
- Lowering cholesterol concentrations and mortality: a quantitative review of primary prevention trials.BMJ, 1990
- Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart StudyJAMA, 1988
- Helsinki Heart Study: Primary-Prevention Trial with Gemfibrozil in Middle-Aged Men with DyslipidemiaNew England Journal of Medicine, 1987